title: Attenuation of Carbon Tetrachloride-Induced Hepatic Toxicity by a Dietary Supplement.
abstract: Advanced liver disease (ALD) is often characterized with overt malnutrition and liver fibrosis. In this study, a dietary supplement (DS) was first developed, including branch chain amino acids, fat soluble vitamins, zinc, medium chain triglycerides, soy lecithin, L-carnitine, and n-3 polyunsaturated fatty acids. Benefits of DS were then tested using an ALD rat model treated with carbon tetrachloride (CCl4) for 6, 8, and 10 weeks, respectively. Our study showed that CCl4-induced drop of serum albumin and ratio of branch chain to aromatic amino acids were significantly prevented at all three time points. DS also mitigated CCl4-induced elevation of classical liver function markers (alanine aminotransferase, aspartate aminotransferase, and bilirubin) at certain time points, depending on specific liver function markers. Moreover, CCl4-induced liver fibrosis was strongly inhibited at all three time points in a transforming growth factor beta (TGF-β) independent manner. These findings indicated multi-faceted benefits of DS in this animal model, suggesting that it could be a useful adjunctive treatment of ALD in clinic.
authors.affiliation: a Abbott Nutrition Research & Development Center , Shanghai , P. R. China.
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Zheng
authors.affiliation: b Abbott Nutrition Research & Development Center , Singapore , Singapore.|c Department of Medicine, Yong Loo Lin School of Medicine , National University of Singapore , Singapore , Singapore.
authors.forename: Richard W
authors.initials: RW
authors.lastname: Gelling
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D024322:Amino Acids, Aromatic / Q000097:blood; D000597:Amino Acids, Branched-Chain / Q000008:administration & dosage / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002252:Carbon Tetrachloride Poisoning / Q000097:blood / Q000628:therapy*; D002331:Carnitine / Q000008:administration & dosage; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology / Q000628:therapy*; D019587:Dietary Supplements; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage; D054709:Lecithins / Q000008:administration & dosage; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D008111:Liver Function Tests; D051381:Rats; D017207:Rats, Sprague-Dawley; D012709:Serum Albumin / Q000032:analysis; D013025:Glycine max / Q000737:chemistry; D014280:Triglycerides / Q000008:administration & dosage; D014815:Vitamins / Q000008:administration & dosage; D015032:Zinc / Q000008:administration & dosage
chemical_list: D024322:Amino Acids, Aromatic; D000597:Amino Acids, Branched-Chain; D015525:Fatty Acids, Omega-3; D054709:Lecithins; D012709:Serum Albumin; D014280:Triglycerides; D014815:Vitamins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D015032:Zinc; D001663:Bilirubin; D002331:Carnitine
keywords: advanced liver disease; dietary supplement; in vivo; liver fibrosis; malnutrition